BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Increases Stock Position in Catalent, Inc. (NYSE:CTLT)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 60.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,659 shares of the company’s stock after buying an additional 13,092 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Catalent were worth $1,949,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of CTLT. Corient Private Wealth LLC increased its holdings in shares of Catalent by 14.5% in the 4th quarter. Corient Private Wealth LLC now owns 23,972 shares of the company’s stock valued at $1,077,000 after acquiring an additional 3,039 shares during the period. Hsbc Holdings PLC grew its stake in Catalent by 89.4% in the fourth quarter. Hsbc Holdings PLC now owns 366,224 shares of the company’s stock valued at $16,453,000 after purchasing an additional 172,902 shares during the last quarter. Parallel Advisors LLC grew its stake in Catalent by 17.4% in the fourth quarter. Parallel Advisors LLC now owns 5,056 shares of the company’s stock valued at $227,000 after purchasing an additional 748 shares during the last quarter. Treasurer of the State of North Carolina raised its holdings in Catalent by 1.0% in the fourth quarter. Treasurer of the State of North Carolina now owns 82,514 shares of the company’s stock worth $3,707,000 after purchasing an additional 785 shares in the last quarter. Finally, Bank of Nova Scotia lifted its position in shares of Catalent by 3,203.9% during the fourth quarter. Bank of Nova Scotia now owns 230,874 shares of the company’s stock valued at $10,373,000 after buying an additional 223,886 shares during the last quarter.

Catalent Stock Performance

Shares of CTLT stock opened at $60.33 on Friday. The business has a fifty day moving average of $59.69 and a 200 day moving average of $57.33. Catalent, Inc. has a 1 year low of $31.80 and a 1 year high of $61.20. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. The firm has a market capitalization of $10.92 billion, a price-to-earnings ratio of -9.89, a price-to-earnings-growth ratio of 2.32 and a beta of 1.15.

Catalent (NYSE:CTLT) last released its earnings results on Thursday, August 29th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.13. The firm had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.23 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. As a group, research analysts expect that Catalent, Inc. will post 0.85 earnings per share for the current year.

Insider Buying and Selling at Catalent

In other news, insider Ricky Hopson sold 662 shares of the stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total value of $39,428.72. Following the sale, the insider now owns 29,974 shares in the company, valued at $1,785,251.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $56.74, for a total transaction of $169,822.82. Following the completion of the transaction, the chief financial officer now directly owns 33,871 shares in the company, valued at $1,921,840.54. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ricky Hopson sold 662 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.56, for a total value of $39,428.72. Following the completion of the sale, the insider now owns 29,974 shares in the company, valued at approximately $1,785,251.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,403 shares of company stock worth $902,503. Company insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on CTLT shares. StockNews.com assumed coverage on shares of Catalent in a research note on Thursday. They set a “sell” rating for the company. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Robert W. Baird reissued a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Barclays upped their target price on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Finally, William Blair reissued a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $59.83.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.